Clinical Trial: Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis

U.S., Sept. 9 -- ClinicalTrials.gov registry received information related to the study (NCT07160608) titled 'Safety and Efficacy of Tarperprumig in Adult Participants With Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis' on July 21.

Brief Summary: The primary objective of this study is to evaluate the safety and tolerability of tarperprumig in participants with newly diagnosed or relapsing anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis.

Study Start Date: Oct. 31

Study Type: INTERVENTIONAL

Condition: Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Intervention: DRUG: Placebo

Participants will receive placebo.

DRUG: Tarperprumig

Participants will receive tarperprumig.

Recruitment Stat...